|
See related Xylocaine Topical information |
|
|
|
Manufacturer |
AstraZeneca |
|
Distributor |
DKSH |
|
Contents |
Lignocaine (Jelly/viscous liqd:HCI). |
|
Indications |
Jelly Draining, probing, cystoscopy & other urological procedures. Prevention & control of pain in procedures involving the male & female urethra, topical treatment of painful urethritis, & anesth lubricant for endotracheal intubation (oral & nasal). Viscous liqd Dumping syndrome. Introduction of probes & catheters into the stomach, esophagoscopy. Production of anesth of irritated or inflamed mucous membranes, the mouth & pharynx; reduce gagging during the taking of X-ray pictures & dental impressions. Spray Surface anesth in dental practice eg before inj, dental impressions, X-ray photograph, removal of calculus; in otorhinolaryngology eg puncture of the maxillary sinus & procedures in the nasal cavity, pharynx & epipharynx. |
|
Dosage |
Jelly Mucous membrane anesth Male 1st instillation: 7-10 mL. After penile clamp: 10 mL. Female A few mL. Viscous liqd Dumping syndrome 10 mL before meals, max tid. Introduction of probes & catheters 15 mL. Esophagoscopy, esophagitis, pharyngitis 10 mL to be swished around in the mouth for at least 1 min before swallowing. Spray Dental practice 1-5 application onto the mucous membranes for 1-2 min. Puncture of the maxillary sinus 3 applications. During delivery Up to 20 applications. Adult 70 kg Max: 200 mg (20 sprays). |
|
Special Precautions |
Viscous liqd No food or drink to be taken for 3 hr after administration. Not >30 mL to be administered in 24 hr. Min intervals between doses: 4 hr. Spray Avoid contact w/ eyes. |
|
Adverse Drug Reactions |
Spray Stimulation & depression of cerebral cortex & medulla.
View ADR Monitoring Form |
|
Pregnancy Category (US FDA) |
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters). |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Xylocaine Topical topical spray |
|
Xylocaine Topical 10 % x 50 mL |
|
|
Xylocaine Topical viscous oromucosal liquid |
|
Xylocaine Topical 2 % x 125 mL |
|
|
Xylocaine Topical jelly |
|
Xylocaine Topical 2 % x 30 g |
|
|
|
Manufacturer: |
AstraZeneca |
|
Distributor: |
DKSH |
|
|
|
